HEPION PHARMACEUTICALS INC (HEPA) Stock Price, Quote, News and Overview
NASDAQ:HEPA - Nasdaq - US4268973025 - Common Stock - Currency: USD
HEPA Quote, Performance and Key Statistics
0.156
+0 (+1.83%)
The current stock price of HEPA is 0.156 USD. In the past month the price decreased by -29.95%. In the past year, price decreased by -95.08%.
HEPA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 70.39 | 868.64B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.81 | 397.52B | ||
| JNJ | JOHNSON & JOHNSON | 16.32 | 392.63B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.92 | 234.20B | ||
| MRK | MERCK & CO. INC. | 11.7 | 226.10B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.6 | 213.35B | ||
| PFE | PFIZER INC | 8.5 | 149.72B | ||
| SNY | SANOFI-ADR | 13.67 | 137.77B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.33 | 116.38B | ||
| GSK | GSK PLC-SPON ADR | 7.94 | 76.32B | ||
| ZTS | ZOETIS INC | 27.87 | 74.44B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.59 | 45.46B |
Related stock screener links
About HEPA
Company Profile
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. The company is headquartered in Edison, New Jersey and currently employs 22 full-time employees. The company went IPO on 2014-02-07. The firm is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. The company is developing rencofilstat as its lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. The company has developed and maintains an artificial intelligence deep machine learning (AI/ML) platform designed to understand disease processes and identify patients that are rencofilstat responders. In addition, its AI/ML can be used to further NASH and HCC clinical development programs.
Company Info
HEPION PHARMACEUTICALS INC
399 Thornall St
Edison NEW JERSEY 08837 US
CEO: Robert Foster
Employees: 22
Company Website: https://hepionpharma.com/
Investor Relations: http://hepionpharma.com/investors/
Phone: 17329024000
HEPION PHARMACEUTICALS INC / HEPA FAQ
What is the stock price of HEPION PHARMACEUTICALS INC today?
The current stock price of HEPA is 0.156 USD. The price increased by 1.83% in the last trading session.
What is the ticker symbol for HEPION PHARMACEUTICALS INC stock?
The exchange symbol of HEPION PHARMACEUTICALS INC is HEPA and it is listed on the Nasdaq exchange.
On which exchange is HEPA stock listed?
HEPA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HEPION PHARMACEUTICALS INC stock?
7 analysts have analysed HEPA and the average price target is 30.6 USD. This implies a price increase of 19515.38% is expected in the next year compared to the current price of 0.156. Check the HEPION PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HEPION PHARMACEUTICALS INC worth?
HEPION PHARMACEUTICALS INC (HEPA) has a market capitalization of 1.09M USD. This makes HEPA a Nano Cap stock.
How many employees does HEPION PHARMACEUTICALS INC have?
HEPION PHARMACEUTICALS INC (HEPA) currently has 22 employees.
Should I buy HEPION PHARMACEUTICALS INC (HEPA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HEPA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HEPA, evaluating the profitability, health, valuation and growth aspects
- HEPION PHARMACEUTICALS INC (HEPA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HEPION PHARMACEUTICALS INC (HEPA) Sales and EPS estimates to see what analysts future expectations are.
- HEPION PHARMACEUTICALS INC (HEPA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HEPION PHARMACEUTICALS INC (HEPA) Insider and Institutional Ownership to learn about the owners and their transactions.
- HEPION PHARMACEUTICALS INC (HEPA) Stock Chart to make your own analysis
- HEPION PHARMACEUTICALS INC (HEPA) Latest news and press-releases to stay up to date.
Does HEPION PHARMACEUTICALS INC (HEPA) stock pay dividends?
HEPA does not pay a dividend.
When does HEPION PHARMACEUTICALS INC (HEPA) report earnings?
HEPION PHARMACEUTICALS INC (HEPA) will report earnings on 2025-04-14, after the market close.
What is the Price/Earnings (PE) ratio of HEPION PHARMACEUTICALS INC (HEPA)?
HEPION PHARMACEUTICALS INC (HEPA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.32).
What is the Short Interest ratio of HEPION PHARMACEUTICALS INC (HEPA) stock?
The outstanding short interest for HEPION PHARMACEUTICALS INC (HEPA) is 45.92% of its float. Check the ownership tab for more information on the HEPA short interest.
HEPA Technical Analysis
HEPA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HEPA. HEPA has a bad profitability rating. Also its financial health evaluation is rather negative.
HEPA Financial Highlights
Over the last trailing twelve months HEPA reported a non-GAAP Earnings per Share(EPS) of -12.32. The EPS decreased by -4.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -611.14% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HEPA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to HEPA. The Buy consensus is the average rating of analysts ratings from 7 analysts.